Help | RSS Feed



Rigel Pharmaceuticals Inc. (NASD:RIGL) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Rigel Pharmaceuticals Inc. (NASD:RIGL) seasonal charts above shows that a Buy Date of June 11 and a Sell Date of September 18 has resulted in a geometric average return of 0.76% above the benchmark rate of the S&P 500 Total Return Index over the past 19 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 19 years by an average of 24.37% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm’s lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken over all responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes Fostamatinib – ITP, Fostamatinib – AIHA, Fostamatinib – IgAN, BGB324 – Oral AXL Inhibitor, ATI-50001 & 50002 – JAK Inhibitors, DS-3032-MDM2 Inhibitor, THF-beta Inhibitors and AZD0449- Inhaled JAK Inhibitor.

To download RIGL seasonal chart data, please log in or Subscribe.

 

Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z


Sponsored By...
Seasonal Advantage Portfolio by CastleMoore